Brain metastasis in stage IV lung adenocarcinoma is frequently missed by symptom-based screening.

ABSTRACT:

Background

Brain metastases (BM) are a major clinical challenge in metastatic lung adenocarcinoma (LUAD), affecting up to 50% of patients during disease progression. Current guidelines do not mandate brain imaging for all metastatic lung cancer patients at diagnosis unless there are neurological symptoms present. However, real-world data on the predictive value of neurological symptoms for BM detection remain scarce.

Methods

This retrospective multicenter study analyzed all consecutive patients diagnosed with stage IV LUAD with molecular assessment in western Sweden from 2016 to 2021 (n = 912). We extracted data from patient charts, imaging referrals, radiology reports and the Swedish National Lung Cancer Registry to determine diagnostic brain imaging (DBI) frequency and mod

SUBMITTER: Sayin SI 

PROVIDER: S-EPMC12804454 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature